Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CXCR2-IN-2 is a selective CXCR2 antagonist that is brain penetrant and orally bioavailable, with IC50 values of 5.2 nM and 1 nM in the β-arrestin assay and CXCR2 Tango assay, respectively. It exhibits approximately 730-fold selectivity over CXCR1 and greater than 1900-fold selectivity over all other chemokine receptors. Furthermore, CXCR2-IN-2 effectively inhibits Gro-α induced CD11b expression in human whole blood, displaying an IC50 of 0.04 μM[1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 1,400.00 | |
50 mg | 8-10 weeks | $ 1,820.00 | |
100 mg | 8-10 weeks | $ 2,820.00 |
Description | CXCR2-IN-2 is a selective CXCR2 antagonist that is brain penetrant and orally bioavailable, with IC50 values of 5.2 nM and 1 nM in the β-arrestin assay and CXCR2 Tango assay, respectively. It exhibits approximately 730-fold selectivity over CXCR1 and greater than 1900-fold selectivity over all other chemokine receptors. Furthermore, CXCR2-IN-2 effectively inhibits Gro-α induced CD11b expression in human whole blood, displaying an IC50 of 0.04 μM[1]. |
Targets&IC50 | CXCR1:3.8 μM (IC50), CXCR2:5.2 nM (IC50) |
In vivo | CXCR2-IN-2 (compound 68) (1-10 mg/kg; p.o.; twice daily for 3 days) dose-dependently reduces neutrophil infiltration in vivo in rat and mouse air pouch models[1]. |
Synonyms | CXCR2-IN-2 |
Molecular Weight | 414.9 |
Formula | C18H23ClN2O5S |
CAS No. | 1838123-21-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 240 mg/mL (578.45 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
CXCR2-IN-2 1838123-21-9 CXCR2IN2 CXCR2 IN 2 CXCR-2-IN-2 inhibitor inhibit